205 related articles for article (PubMed ID: 29257709)
1. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
Zhu J; Liao R; Su C; Liang D; Wu J; Qiu K; Li J
Expert Rev Anticancer Ther; 2018 Feb; 18(2):193-198. PubMed ID: 29257709
[TBL] [Abstract][Full Text] [Related]
2. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
Iacovelli R; Ciccarese C; Bria E; Romano M; Fantinel E; Bimbatti D; Muraglia A; Porcaro AB; Siracusano S; Brunelli M; Mazzarotto R; Artibani W; Tortora G
Clin Genitourin Cancer; 2018 Jun; 16(3):e645-e653. PubMed ID: 29339044
[TBL] [Abstract][Full Text] [Related]
3. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
6. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
[TBL] [Abstract][Full Text] [Related]
7. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
8. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
[TBL] [Abstract][Full Text] [Related]
9. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
10. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
12. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M; Lebrun-Vignes B; Pariente A; Shaffer CM; Malouf GG; Dureau P; Potey C; Funck-Brentano C; Roden DM; Moslehi JJ; Salem JE
Arch Cardiovasc Dis; 2020 Jan; 113(1):9-21. PubMed ID: 31685432
[TBL] [Abstract][Full Text] [Related]
13. Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan.
Miyake H; Hara T; Terakawa T; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Apr; 15(2):313-319. PubMed ID: 27424256
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
15. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
Lu-Yao G; Nikita N; Keith SW; Nightingale G; Gandhi K; Hegarty SE; Rebbeck TR; Chapman A; Kantoff PW; Cullen J; Gomella L; Kelly WK
Eur Urol; 2020 Feb; 77(2):158-166. PubMed ID: 31420248
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials.
Zheng X; Zhao X; Xu H; Han X; Xu H; Dong X; Peng R; Yang L; Wei Q; Ai J
Medicine (Baltimore); 2019 Nov; 98(44):e17748. PubMed ID: 31689828
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
[TBL] [Abstract][Full Text] [Related]
18. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
19. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
Tsao PA; Caram MEV
Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
